Silence Signs AstraZeneca To $400M Respiratory Drug Deal July 11, 2007 By Jennifer Boggs In its largest deal to date, RNAi firm Silence Therapeutics plc is partnering with AstraZeneca plc in a potential £200 million (US$400 million) to develop drugs against respiratory disease targets. (BioWorld International)Read More
CureVac Receives €13M To Boost mRNA Cancer Vaccines July 11, 2007 By Cormac Sheridan No AbstractRead More
RSS